{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:54:53Z","timestamp":1791222893160,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"name":"The Netherlands Ministry of Foreign Affairs in partnership with Stichting Aids Fonds","award":["grant 12454"],"award-info":[{"award-number":["grant 12454"]}]},{"name":"de Grote Onderneming","award":["Amsterdam Diner 2008"],"award-info":[{"award-number":["Amsterdam Diner 2008"]}]},{"name":"Clinical Interventions against Poverty related Diseases","award":["grant W.07.05.204.00"],"award-info":[{"award-number":["grant W.07.05.204.00"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1093\/jac\/dkw218","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T04:48:12Z","timestamp":1466916492000},"page":"2918-2927","source":"Crossref","is-referenced-by-count":91,"title":["Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa"],"prefix":"10.1093","volume":"71","author":[{"given":"T. Sonia","family":"Boender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy M.","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragna S.","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raph L.","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Ondoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Wellington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Siwale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculate","family":"Nankya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kaudha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alani Sulaimon","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette E.","family":"Botes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Steegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job C. J.","family":"Calis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias F.","family":"Rinke de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim C. E.","family":"Sigaloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"2016092200323771000_71.10.2918.1","unstructured":"WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV . 2015. http:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease-arv\/en\/ ."},{"key":"2016092200323771000_71.10.2918.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ400"},{"key":"2016092200323771000_71.10.2918.3","unstructured":"WHO. The HIV Drug Resistance Report\u20132012 . 2012. http:\/\/www.who.int\/hiv\/pub\/drugresistance\/report2012\/en\/ ."},{"key":"2016092200323771000_71.10.2918.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70255-9"},{"key":"2016092200323771000_71.10.2918.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61038-1"},{"key":"2016092200323771000_71.10.2918.6","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318227fc34"},{"key":"2016092200323771000_71.10.2918.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69158-7"},{"key":"2016092200323771000_71.10.2918.8","unstructured":"WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection\u2014Recommendations for a Public Health Approach . 2013. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/download\/en\/ ."},{"key":"2016092200323771000_71.10.2918.9","unstructured":"WHO. Policy Brief: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What's New . 2015. http:\/\/www.who.int\/hiv\/pub\/arv\/policy-brief-arv-2015\/en\/ ."},{"key":"2016092200323771000_71.10.2918.10","unstructured":"WHO. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach\u20142010 Revision . 2010. http:\/\/www.who.int\/hiv\/pub\/arv\/adult2010\/en\/ ."},{"key":"2016092200323771000_71.10.2918.11","unstructured":"WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach (2006 Revision) . 2006. http:\/\/www.who.int\/hiv\/pub\/arv\/adult\/en\/ ."},{"key":"2016092200323771000_71.10.2918.12","first-page":"CD004772","article-title":"Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age","volume":"issue 5","author":"Penazzato","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2016092200323771000_71.10.2918.13","unstructured":"Cipla. Cipla Announces US FDA Approval for the World's First Paediatric Lopinavir and Ritonavir Oral Pellets . Press Release. 2015. http:\/\/www.cipla.co.za\/cipla-announces-us-fda-approval-for-the-worlds-first-paediatric-lopinavir-and-ritonavir-oral-pellets ."},{"key":"2016092200323771000_71.10.2918.14","doi-asserted-by":"publisher","DOI":"10.1086\/381784"},{"key":"2016092200323771000_71.10.2918.15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis261"},{"key":"2016092200323771000_71.10.2918.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311274"},{"key":"2016092200323771000_71.10.2918.17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)00061-7"},{"key":"2016092200323771000_71.10.2918.18","unstructured":"M\u00e9decins Sans Fronti\u00e8res. Untangling the Web of Antiretroviral Price Reductions , 17th Edition. 2014. http:\/\/www.msfaccess.org\/content\/untangling-web-antiretroviral-price-reductions-17th-edition-\u2013-july-2014 ."},{"key":"2016092200323771000_71.10.2918.19","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2010"},{"key":"2016092200323771000_71.10.2918.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2011.00943.x"},{"key":"2016092200323771000_71.10.2918.21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.20.12773-12782.2005"},{"key":"2016092200323771000_71.10.2918.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00986-09"},{"key":"2016092200323771000_71.10.2918.23","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","author":"Wensing","year":"2015","journal-title":"Top Antivir Med"},{"key":"2016092200323771000_71.10.2918.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04215-14"},{"issue":"Suppl 3","key":"2016092200323771000_71.10.2918.25","doi-asserted-by":"crossref","first-page":"19740","DOI":"10.7448\/IAS.17.4.19740","article-title":"Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand","volume":"17","author":"Teeranaipong","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2016092200323771000_71.10.2918.26","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq192"},{"key":"2016092200323771000_71.10.2918.27","first-page":"817506","article-title":"Barriers to initiation of pediatric HIV treatment in Uganda: a mixed-method study","volume":"2012","author":"Boender","year":"2012","journal-title":"AIDS Res Treat"},{"key":"2016092200323771000_71.10.2918.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2009.11.011"},{"key":"2016092200323771000_71.10.2918.29","unstructured":"Bronze M , Moodley K , Steegen K et al . Development and validation of a one-step genotyping protocol encompassing HIV-1 protease and reverse transcriptase for patient antiretroviral drug resistance monitoring. In: International Conference of the African Society for Laboratory Medicine, Cape Town, South Africa, 2012."},{"key":"2016092200323771000_71.10.2918.30","unstructured":"Lukhwareni A , Bronze M , Ledwaba J et al . Validation of a robust in-house genotyping assay for the detection of HIV-1 antiretroviral drug resistance. In: Pathpoint Conference, Cape Town, South Africa, 2012."},{"key":"2016092200323771000_71.10.2918.31","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"2016092200323771000_71.10.2918.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2013.04.032"},{"key":"2016092200323771000_71.10.2918.33","doi-asserted-by":"crossref","unstructured":"Kityo C , Sigaloff KC , Boender TS et al . HIV drug resistance among children initiating first-line antiretroviral treatment in Uganda. AIDS Res Hum Retroviruses 2016; doi:10.1089\/aid.2015.0215 .","DOI":"10.1089\/aid.2015.0215"},{"key":"2016092200323771000_71.10.2918.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70149-9"},{"key":"2016092200323771000_71.10.2918.35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ656"},{"key":"2016092200323771000_71.10.2918.36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ556"},{"issue":"Suppl 6","key":"2016092200323771000_71.10.2918.37","doi-asserted-by":"crossref","first-page":"20265","DOI":"10.7448\/IAS.18.7.20265","article-title":"Sequencing paediatric antiretroviral therapy in the context of a public health approach","volume":"18","author":"Boerma","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"2016092200323771000_71.10.2918.38","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0218"},{"key":"2016092200323771000_71.10.2918.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis254"},{"key":"2016092200323771000_71.10.2918.40","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f5379a"},{"key":"2016092200323771000_71.10.2918.41","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182a009e4"},{"key":"2016092200323771000_71.10.2918.42","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181e47609"},{"key":"2016092200323771000_71.10.2918.43","doi-asserted-by":"publisher","DOI":"10.2174\/157016210791111098"},{"key":"2016092200323771000_71.10.2918.44","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283584500"},{"key":"2016092200323771000_71.10.2918.45","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt198"},{"key":"2016092200323771000_71.10.2918.46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068995"},{"key":"2016092200323771000_71.10.2918.47","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2002.00101.x"},{"key":"2016092200323771000_71.10.2918.48","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000243211.36690.d5"},{"key":"2016092200323771000_71.10.2918.49","unstructured":"WHO. Technical Update on Treatment Optimization: Use of Tenofovir in HIV-Infected Children and Adolescents: A Public Health Perspective . June 2012. http:\/\/apps.who.int\/iris\/bitstream\/10665\/70944\/1\/9789241503822_eng.pdf ."},{"key":"2016092200323771000_71.10.2918.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00536-8"},{"key":"2016092200323771000_71.10.2918.51","unstructured":"AIDSinfo. Etravirine (ETR, Intelence, TMC 125) . 2015. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/2\/pediatric-arv-guidelines\/124\/etravirine ."},{"key":"2016092200323771000_71.10.2918.52","unstructured":"AIDSinfo. Rilpivirine (RPV, Edurant, TMC 278) . 2015. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/2\/pediatric-arv-guidelines\/126\/rilpivirine ."},{"key":"2016092200323771000_71.10.2918.53","first-page":"642","article-title":"2014 update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"2016092200323771000_71.10.2918.54","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv383"},{"key":"2016092200323771000_71.10.2918.55","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00087-9"},{"key":"2016092200323771000_71.10.2918.56","doi-asserted-by":"crossref","unstructured":"Boender TS , Hamers RL , Ondoa P et al . Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa. J Infect Dis 2016; in press.","DOI":"10.1093\/infdis\/jiw219"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/10\/2918\/17429741\/dkw218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T23:07:29Z","timestamp":1600816049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,9,22]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1093\/jac\/dkw218"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw218","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}